Spero Therapeutics (NASDAQ:SPRO) Stock Rating Cut to “Strong Sell” at Wall Street Zen

Spero Therapeutics (NASDAQ:SPRO – Get Free Report) was downgraded by analysts at Wall Street Zen from a “sell” rating to a “strong sell” rating in a note issued to investors on Saturday, Wall Street Zen reports.

Several other equities research analysts also recently commented on SPRO. Cantor Fitzgerald began coverage on shares of Spero Therapeutics in a research report on Wednesday, October 28th. They set an “overweight” rating and a $6.00 target price on the stock. Weiss Ratings upgraded shares of Spero Therapeutics from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Tuesday. HC Wainwright upped their price target on shares of Spero Therapeutics from $5.00 to $6.00 and gave the company a “buy” rating in a research report on Monday, September 14th. Zacks Research raised shares of Spero Therapeutics to a “hold” rating in a research note on Monday, September 14th. Finally, Compass Point upgraded shares of Spero Therapeutics to a “neutral” rating in a report on Monday, September 14th. Two research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat.com, Spero Therapeutics presently has an average rating of “Hold” and a consensus price target of $6.00.

View Our Latest Stock Report on SPRO

Spero Therapeutics Trading Down 0.0%

Shares of SPRO stock opened at $1.00 on Friday. The business’s 50-day moving average price is $1.14 and its 200-day moving average price is $1.91. Spero Therapeutics has a 12 month low of $0.95 and a 12 month high of $3.08. The firm has a market capitalization of $58.23 million, a price-to-earnings ratio of -1.92 and a beta of 1.59.

Spero Therapeutics (NASDAQ:SPRO – Get Free Report) last released its quarterly earnings results on Thursday, November 12th. The company reported ($0.76) earnings per share for the quarter, missing the consensus estimate of ($0.47) by ($0.29). Spero Therapeutics had a return on equity of 10.54% and a net margin of 24.90%. On average, sell-side analysts predict that Spero Therapeutics will post -0.97 earnings per share for the current fiscal year.

Insider Activity at Spero Therapeutics

In other news, insider Esther Rajavelu sold 40,851 shares of the stock in a transaction dated Monday, November 9th. The stock was sold at an average price of $1.04, for a total value of $42,485.04. Following the completion of the sale, the insider owned 946,000 shares of the company’s stock, valued at approximately $983,840. This represents a 4.14% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Company insiders own 2.90% of the company’s stock.

Hedge Funds Weigh In On Spero Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Susquehanna Fundamental Investments LLC acquired a new stake in Spero Therapeutics during the 2nd quarter valued at approximately $36,000. Global Retirement Partners LLC acquired a new position in shares of Spero Therapeutics in the 2nd quarter worth approximately $55,000. Empowered Funds LLC acquired a new position in shares of Spero Therapeutics in the 3rd quarter worth approximately $77,000. Marshall Wace LLP acquired a new position in shares of Spero Therapeutics in the 3rd quarter worth approximately $236,000. Finally, GSA Capital Partners LLP bought a new stake in shares of Spero Therapeutics in the 2nd quarter valued at $632,000. 25.60% of the stock is owned by institutional investors and hedge funds.

About Spero Therapeutics

(Get Free Report)

Spero Therapeutics, Inc. is a biopharmaceutical company focused on developing treatments for serious and difficult-to-treat bacterial infections. Its work has centered on antibiotic candidates intended to address infections for which existing treatment options may be limited. The company’s pipeline has included tebipenem HBr, an oral antibiotic candidate studied for complicated urinary tract infections, and programs targeting drug-resistant Gram-negative bacteria and nontuberculous mycobacterial infections.

Further Reading

Analyst Recommendations for Spero Therapeutics (NASDAQ:SPRO)

Receive News & Ratings for Spero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.